Your session is about to expire
What is Glatopa
GlatiramerThe Generic name of this drug
Treatment SummaryGlatiramer acetate is a medication made of four natural amino acids: glutamic acid, alanine, tyrosine, and lysine. It is an immunomodulator used to reduce the frequency of relapses in people with relapsing-remitting multiple sclerosis. The average molecular weight of glatiramer acetate is 5,000-9,000 daltons.
Copaxoneis the brand name
Glatopa Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Copaxone
Glatiramer
2002
9
Approved as Treatment by the FDA
Glatiramer, otherwise known as Copaxone, is approved by the FDA for 1 uses such as Multiple Sclerosis .Multiple Sclerosis
Helps manage Multiple Sclerosis
Effectiveness
How Glatopa Affects PatientsGlatiramer acetate is a mix of four amino acids (L-glutamic acid, L-alanine, L-tyrosine, and L-lysine) used to treat relapsing multiple sclerosis. It works by helping to modify the immune system processes that cause MS. Patients taking glatiramer acetate have been shown to have fewer relapses than those taking a placebo or IFNb-1a. However, some patients experience side effects after taking the drug, including chest pain, injection site side effects, and hepatic injury. There is also a chance that glatiramer acetate
How Glatopa works in the bodyGlatiramer acetate works to treat multiple sclerosis by changing how the body's immune system reacts. It binds to certain molecules on cells that are involved in MS and prevents them from causing inflammation. It also encourages the body to make anti-inflammatory cells that can cross the blood-brain barrier and produce helpful cytokines. These cells help suppress MS and can even induce production of T-regulatory cells that further suppress the disease.
When to interrupt dosage
The recommended dosage of Glatopa is contingent upon the indicated condition. The quantity of dosage fluctuates in accordance with the technique of delivery (e.g. Solution - Subcutaneous or Injection, solution - Subcutaneous) featured in the table beneath.Condition
Dosage
Administration
Carcinoma in Situ
20.0 mg, , 20.0 mg/mL, 40.0 mg/mL
, Subcutaneous, Powder, for solution, Powder, for solution - Subcutaneous, Solution, Solution - Subcutaneous, Injection, solution - Subcutaneous, Injection, solution, Injection, Injection - Subcutaneous
Relapsing Remitting Multiple Sclerosis
20.0 mg, , 20.0 mg/mL, 40.0 mg/mL
, Subcutaneous, Powder, for solution, Powder, for solution - Subcutaneous, Solution, Solution - Subcutaneous, Injection, solution - Subcutaneous, Injection, solution, Injection, Injection - Subcutaneous
active Secondary Progressive Multiple Sclerosis (SPMS)
20.0 mg, , 20.0 mg/mL, 40.0 mg/mL
, Subcutaneous, Powder, for solution, Powder, for solution - Subcutaneous, Solution, Solution - Subcutaneous, Injection, solution - Subcutaneous, Injection, solution, Injection, Injection - Subcutaneous
Multiple Sclerosis
20.0 mg, , 20.0 mg/mL, 40.0 mg/mL
, Subcutaneous, Powder, for solution, Powder, for solution - Subcutaneous, Solution, Solution - Subcutaneous, Injection, solution - Subcutaneous, Injection, solution, Injection, Injection - Subcutaneous
Warnings
Glatopa has two demarcated contraindications, so it should not be utilized when suffering from any of the ailments specified in the following table.Glatopa ContraindicationsCondition
Risk Level
Notes
Severe Hypersensitivity Reactions
Do Not Combine
Glatiramer may interact with Pulse Frequency
Severe Hypersensitivity Reactions
Do Not Combine
Glatiramer may interact with Pulse Frequency
Common Glatopa Drug Interactions
Drug Name
Risk Level
Description
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Glatiramer is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abetimus
Major
The risk or severity of adverse effects can be increased when Glatiramer is combined with Abetimus.
Acteoside
Major
The risk or severity of adverse effects can be increased when Glatiramer is combined with Acteoside.
Antilymphocyte immunoglobulin (horse)
Major
The risk or severity of adverse effects can be increased when Glatiramer is combined with Antilymphocyte immunoglobulin (horse).
Apremilast
Major
The risk or severity of adverse effects can be increased when Glatiramer is combined with Apremilast.
Glatopa Toxicity & Overdose RiskIn mice and rats given 15 times the normal dose of glatiramer acetate, there were no reports of increased cancer risk. Tests in the lab did not find any mutagenic effects. Animals given the drug did not have any reproductive or developmental issues. If someone takes too much glatiramer acetate, they may experience severe side effects such as liver damage, loss of fat, or dead skin at the injection site. Treatment for an overdose should focus on managing the symptoms and providing supportive care.
Glatopa Novel Uses: Which Conditions Have a Clinical Trial Featuring Glatopa?
193 active trials are being carried out to determine the efficacy of Glatopa in treating Multiple Sclerosis.Condition
Clinical Trials
Trial Phases
Relapsing Remitting Multiple Sclerosis
13 Actively Recruiting
Not Applicable, Phase 3, Phase 1, Phase 2, Phase 4
Multiple Sclerosis
195 Actively Recruiting
Phase 3, Not Applicable, Phase 2, Phase 1, Phase 4, Early Phase 1
active Secondary Progressive Multiple Sclerosis (SPMS)
0 Actively Recruiting
Carcinoma in Situ
5 Actively Recruiting
Not Applicable, Phase 4
Glatopa Reviews: What are patients saying about Glatopa?
2.3Patient Review
4/29/2016 I am joining the ranks of those who have had issues after switching from Copaxone to Glatopa. I was fine for five years while on Copaxone, but soon after being switched over in January, I developed uvitis and now I'm experiencing a flare-up that isn't responding well to prednisone.
2Patient Review
10/1/2015 About three months ago, my insurance company switched me to the generic form of this medication. Recently, I've been feeling even more tired and have started forgetting things like appointments and conversations. I'm going to see a doctor soon to discuss this further.
1.3Patient Review
2/23/2019 I was on copaxone for about 7 years. No increases in legions during that time. My insurance forced me to switch to generic. After 1 year on generic, legions more than doubled on brain and quadrupled on spine. Doctor immediately switched me to Gilenya. 1 year later, no advancement in legions or worsening of pain and fatigue. Thought it was just my time to get worse until looking into it again and seeing like issues; however, upon further research I discovered that this is a common occurrence with this medication changeover.
1.3Patient Review
4/20/2019 Cigna forced me to switch from Copaxone to Glatopa, and soon after I started having severe symptoms. Numbness, tingling in my extremities, difficulty using my hands, clumsiness in one foot, and difficulty thinking are just some of the problems I experienced. This drug was a big mistake.
1Patient Review
12/12/2015 I was moved to this generic Glatopa after 12 years on Copaxone. I had a few attacks, some minor numbness and fatigue before, but since switching to Glatopa I've had two major attacks within 3 months. The first one caused me to lose my hearing in my left ear, and now I'm having trouble with my legs - they're weak and unsteady. I'm not happy with Glatopa at all.
1Patient Review
12/30/2015 Glatopa was a terrible switch for me after being on Copaxone for four years without any issues. I started losing feeling in my left arm and face, and the injections became more difficult and painful.
1Patient Review
2/8/2017 I started taking Glatopa 9-15. I am a 63 year old male on disability since 10-12. I live in Florida and the summers are really bad on me. I experience extreme fatigue doing any type of activity that anyone else could do with ease. Winter is much kinder to me but I still go through a lesser severe fatigue. I do not believe that Glatopa helps.
1Patient Review
10/27/2018 I had a lot of negative side effects with this medication, including problems with my memory and depression. I also experienced pain in my joints and fatigue. Copaxone was much better for me and didn't have any of these problems, so I had to switch back.
1Patient Review
8/16/2017 I much preferred the copaxone to this treatment. I felt like I had more support and people actually reaching out to see if I was doing alright.
Patient Q&A Section about glatopa
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.What does Glatopa treat?
"The FDA has approved Glatopa for the treatment of MS in adults."
Answered by AI
What type of drug is Glatopa?
"The usage of Glatopa is to treat patients with relapsing forms of multiple sclerosis, including those who have experienced a first clinical episode and have magnetic resonance imaging features consistent with MS. Glatopa is the generic version of Copaxone."
Answered by AI
Is Glatopa the same as Copaxone?
"The primary difference between Glatopa and Copaxone is that Glatopa is a generic version of the latter. In other words, the active ingredient, clinical benefits, and method of administration are all identical between the two medication options; however, Glatopa is typically more affordable than Copaxone."
Answered by AI
How long does it take for Glatopa to work?
"The effects of Copaxone may not be noticeable for several months after starting injections, with most people reporting it takes six to nine months to notice an effect. In some people it may take longer for the effects to be noticeable."
Answered by AI